3 Tertiary Hospital Operator, Pathology Lab Network and Infusion Set and Syringe Maker Stocks With a Strong Future Roadmap: Global Health, Dr. Lal PathLabs and Poly Medicure

Hospital, diagnostics and medical device stocks bring together companies with a visible plan for the years ahead. Global Health, Dr. Lal PathLabs and Poly Medicure cover a tertiary care hospital chain, a national diagnostics network and a single-use medical devices maker.

This list covers three hospital, diagnostics and medical device stocks with complete current figures: Global Health, Dr. Lal PathLabs and Poly Medicure. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Hospital, Diagnostics and Medical Device Stocks?

Hospital, diagnostics and medical device stocks are listed healthcare companies that run hospitals, operate diagnostic labs and make single-use medical devices. Their earnings depend on patient volumes, test counts, device orders and pricing.

Hospital, Diagnostics and Medical Device Stocks at a Glance

On valuation, Dr. Lal PathLabs and Poly Medicure trade at a P/E below the industry P/E, while Global Health trades above it, which reflects the growth the market already expects. Readers comparing hospital, diagnostics and medical device stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in hospital, diagnostics and medical device stocks can use the coming numbers to test whether growth is holding.

Why Do Hospital, Diagnostics and Medical Device Stocks Have a Strong Roadmap in India?

Hospital, diagnostics and medical device stocks have a strong roadmap in India because rising incomes, health insurance cover and a growing preference for quality care keep lifting spending on treatment, testing and devices.

• Insurance cover. More people can afford quality treatment.
• Testing volumes. Early diagnosis lifts routine test counts.
• Device exports. Global buyers add Indian medical device makers.

Why Global Health Features Among These Hospital, Diagnostics and Medical Device Stocks

Among the hospital, diagnostics and medical device stocks on this list, Global Health, which operates the Medanta brand, runs tertiary-care hospitals led by its flagship campus in Gurugram, along with facilities in Lucknow, Patna, Ranchi, Indore and Noida.

In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%.

Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6.

Roadmap: Management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.

What to watch: Watch the ramp-up speed of newer hospitals and the pace of doctor additions at each site.

Why Dr. Lal PathLabs Features Among These Hospital, Diagnostics and Medical Device Stocks

Among the tertiary care hospital company shares on this list, Dr. Lal PathLabs is one of India's best-known diagnostics companies, operating a national reference laboratory with a hub-and-spoke network of labs, patient service centres and collection points.

The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6.

Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore.

Roadmap: Its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.

What to watch: Follow test volumes per patient and the balance between routine and specialised tests.

Why Poly Medicure Features Among These Hospital, Diagnostics and Medical Device Stocks

Among the three companies on this list, Poly Medicure makes single-use medical devices such as infusion sets, syringes, catheters, blood management products and dialysis consumables, and it exports to many countries.

Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%.

In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6.

Roadmap: The company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.

What to watch: Track export growth, new product approvals and plant capacity use.

Global Health vs Dr. Lal PathLabs vs Poly Medicure on Key Financials

The table below sets the three hospital, diagnostics and medical device stocks side by side on revenue, profit and margin, using reported figures.

Dr. Lal PathLabs posts the highest return on equity in this group at 20.1%. Global Health has the largest FY26 revenue at Rs 4,509 crore, and Poly Medicure shows the fastest revenue growth with a 20.0% compound annual rate. A useful habit with hospital, diagnostics and medical device stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Hospital, Diagnostics and Medical Device Stocks

Every theme carries risks that deserve a check before any decision. For these hospital, diagnostics and medical device stocks, the main points are: Long-term tertiary care hospital company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulation. Pricing rules can affect healthcare earnings.
• Capacity additions. New beds and labs take time to fill.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter hospital, diagnostics and medical device stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Hospital, Diagnostics and Medical Device Stocks

Hospital, diagnostics and medical device stocks suit investors who prefer to study business strength before price moves. Global Health, Dr. Lal PathLabs and Poly Medicure each have a clear plan to expand. Based on the 23 October 2026 close, Global Health trades at Rs 1,185, Dr. Lal PathLabs at Rs 1,838.2 and Poly Medicure at Rs 1,444. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these hospital, diagnostics and medical device stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track hospital, diagnostics and medical device stocks, set price alerts and get research-backed stock ideas.

What are hospital, diagnostics and medical device stocks?

Ans. Hospital, diagnostics and medical device stocks are listed healthcare companies that run hospitals, operate diagnostic labs and make single-use medical devices. Their earnings depend on patient volumes, test counts, device orders and pricing. This list looks at three of them, Global Health, Dr. Lal PathLabs and Poly Medicure, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.

Which hospital, diagnostics and medical device stocks are covered in this list?

Ans. This list covers Global Health, Dr. Lal PathLabs and Poly Medicure. Based on the 23 October 2026 close, Global Health traded at Rs 1,185, Dr. Lal PathLabs at Rs 1,838.2 and Poly Medicure at Rs 1,444. Their return on equity ranges from 10.4% to 20.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 20.0%.

Why do hospital, diagnostics and medical device stocks have a strong future roadmap in India?

Ans. Hospital, diagnostics and medical device stocks have a strong roadmap in India because rising incomes, health insurance cover and a growing preference for quality care keep lifting spending on treatment, testing and devices. The main drivers are as follows. Insurance cover. More people can afford quality treatment. Testing volumes. Early diagnosis lifts routine test counts. Device exports. Global buyers add Indian medical device makers. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Global Health performed financially?

Ans. Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6. Looking ahead, management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.

How has Dr. Lal PathLabs performed financially?

Ans. Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.

How has Poly Medicure performed financially?

Ans. Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6. Looking ahead, the company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.

What risks should investors check before buying hospital, diagnostics and medical device stocks?

Ans. Investors should check a few risks before buying hospital, diagnostics and medical device stocks. Regulation. Pricing rules can affect healthcare earnings. Capacity additions. New beds and labs take time to fill. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of hospital, diagnostics and medical device stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.